PFBT
MLYS icon

Parkside Financial Bank & Trust’s Mineralys Therapeutics MLYS Stock Holding History

Parkside Financial Bank & Trust’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$948 Hold
35
– – ﹤0.01% 2378
2025
Q4 		$1.27K Hold
35
– – ﹤0.01% 2254
2025
Q3 		$1.33K Hold
35
– – ﹤0.01% 2167
2025
Q2 		$474 Buy
+35
New +$507 ﹤0.01% 2581

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Parkside Financial Bank & Trust's MLYS Position: Q1 2026 in Review

Parkside Financial Bank & Trust held its Mineralys Therapeutics (MLYS) position steady in Q1 2026 at 35 shares worth $948. The position accounts for ﹤0.01% of the portfolio, ranked #2378.

Parkside Financial Bank & Trust first reported a position in MLYS in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.33K in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Parkside Financial Bank & Trust held 35 shares of Mineralys Therapeutics worth $948 as of Q1 2026.
  • Parkside Financial Bank & Trust left its Mineralys Therapeutics share count unchanged in Q1 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2378 holding.
  • Parkside Financial Bank & Trust first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Parkside Financial Bank & Trust's Mineralys Therapeutics position peaked at $1.33K in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.